Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial

By afschroeder • May 2, 2026

Martínez E, Watanabe M, Hoffman R, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Sponseller CA, Lu AB, Lu MT, Aberg JA, Currier JS, Douglas PS, Ribaudo HJ, Grinspoon SK; REPRIEVE Investigators. Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial. Lancet HIV. 2026 May;13(5):e327-e337. doi: 10.1016/S2352-3018(26)00036-6. PMID: 42067280.

Tags: Cardiology/Epi, Infectious Diseases, Publications

Cardiovascular-specific PTH1R activation enhances exercise-induced cardiac remodeling in a mouse model of calcific atherosclerosis

Hon A, Lu M, Shao XM, Demer LL, Tintut Y. Cardiovascular-specific PTH1R activation enhances exercise-induced cardiac remodeling in a mouse model of calcific atherosclerosis. Biochem[...]

In-Hospital Initiation of SGLT2 Inhibitors in Patients with Acute Heart Failure: A Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis

Ahmed M, Rana JS, Sajjad L, Zulfiqar E, Chandak V, Tul Ain Q, Ahmed R, Mentz RJ, Fonarow GC. In-Hospital Initiation of SGLT2 Inhibitors in[...]

The Research Post

Calais J, Czernin J. The Research Post. J Nucl Med. 2026 May 1;67(5):663. doi: 10.2967/jnumed.126.272505. PMID: 42067215.